High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support refractory multiple myeloma

G. J. Ventura; B. Barlogie; J. P. Hester; J. C. Yau; C. F. LeMaistre; R. O. Wallerstein; J. A. Spinolo; K. A. Dicke; L. H. Horwitz; R. Alexanian

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support refractory multiple myeloma

G. J. Ventura, B. Barlogie, J. P. Hester, J. C. Yau, C. F. LeMaistre, R. O. Wallerstein, J. A. Spinolo, K. A. Dicke, L. H. Horwitz, R. Alexanian

Research output: Contribution to journal › Article › peer-review

45 Scopus citations

Abstract

Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support. Seven patients had marked marrow plasmacytosis (>30%) and four had extensive pelvic bone disease precluding autologous marrow harvest. Four patients responded with a median remission duration of 7 months. Recovery of granulocytes and platelets occurred promptly in 10 evaluable patients with complete hematologic recovery. Autologous blood stem cells can provide safe and effective support for high dose CBV treatment of myeloma patients with extensive marrow plasmacytosis. The short remissions call for better cytoreductive regimens with consideration for earlier use when the myeloma may be more responsive to therapy.

Original language	English
Pages (from-to)	265-268
Number of pages	4
Journal	Bone Marrow Transplantation
Volume	5
Issue number	4
State	Published - 1990
Externally published	Yes

Cite this

@article{95159888dc1c4cee9c511a78e9b1bbf5,

title = "High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support refractory multiple myeloma",

abstract = "Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support. Seven patients had marked marrow plasmacytosis (>30%) and four had extensive pelvic bone disease precluding autologous marrow harvest. Four patients responded with a median remission duration of 7 months. Recovery of granulocytes and platelets occurred promptly in 10 evaluable patients with complete hematologic recovery. Autologous blood stem cells can provide safe and effective support for high dose CBV treatment of myeloma patients with extensive marrow plasmacytosis. The short remissions call for better cytoreductive regimens with consideration for earlier use when the myeloma may be more responsive to therapy.",

author = "Ventura, {G. J.} and B. Barlogie and Hester, {J. P.} and Yau, {J. C.} and LeMaistre, {C. F.} and Wallerstein, {R. O.} and Spinolo, {J. A.} and Dicke, {K. A.} and Horwitz, {L. H.} and R. Alexanian",

year = "1990",

language = "English",

volume = "5",

pages = "265--268",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "4",

}

TY - JOUR

T1 - High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support refractory multiple myeloma

AU - Ventura, G. J.

AU - Barlogie, B.

AU - Hester, J. P.

AU - Yau, J. C.

AU - LeMaistre, C. F.

AU - Wallerstein, R. O.

AU - Spinolo, J. A.

AU - Dicke, K. A.

AU - Horwitz, L. H.

AU - Alexanian, R.

PY - 1990

Y1 - 1990

N2 - Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support. Seven patients had marked marrow plasmacytosis (>30%) and four had extensive pelvic bone disease precluding autologous marrow harvest. Four patients responded with a median remission duration of 7 months. Recovery of granulocytes and platelets occurred promptly in 10 evaluable patients with complete hematologic recovery. Autologous blood stem cells can provide safe and effective support for high dose CBV treatment of myeloma patients with extensive marrow plasmacytosis. The short remissions call for better cytoreductive regimens with consideration for earlier use when the myeloma may be more responsive to therapy.

AB - Eleven patients with advanced multiple myeloma refractory to standard doses of alkylating agents and salvage therapy with vincristine, adriamycin and dexamethasone (VAD) were treated with high dose cyclophosphamide, BCNU and VP-16 (CBV) with autologous blood stem cell support. Seven patients had marked marrow plasmacytosis (>30%) and four had extensive pelvic bone disease precluding autologous marrow harvest. Four patients responded with a median remission duration of 7 months. Recovery of granulocytes and platelets occurred promptly in 10 evaluable patients with complete hematologic recovery. Autologous blood stem cells can provide safe and effective support for high dose CBV treatment of myeloma patients with extensive marrow plasmacytosis. The short remissions call for better cytoreductive regimens with consideration for earlier use when the myeloma may be more responsive to therapy.

UR - http://www.scopus.com/inward/record.url?scp=0025329962&partnerID=8YFLogxK

M3 - Article

C2 - 1970939

AN - SCOPUS:0025329962

SN - 0268-3369

VL - 5

SP - 265

EP - 268

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 4

ER -

High dose cyclophosphamide, BCNU and VP-16 with autologous blood stem cell support refractory multiple myeloma

Abstract

Fingerprint

Cite this